Search

Clinical leadership is necessary to improve the performance of large public hospitals. Trainee medical officers (TMOs) are important stakeholders in organisation-wide initiatives that affect the medical workforce and support clinician engagement. This case study describes the development of a representative body known as the ‘TMO Forum’ within the Central Adelaide Local Health Network as a mechanism to promote engagement between medical trainees and the hospital executive to facilitate escalation and discussion of system-based issues. Over the past 8 years, this group has evolved into a community of practice with steady and sustained growth since inception. Trainees have fostered relationships with the executive, and have engaged in leadership and quality improvement initiatives. Here we explore the evolution, value and barriers to success of the TMO Forum. Our discussion is supplemented with findings from anonymous online evaluation surveys of both the TMO and executive stakeholder groups. We propose that initiatives such as the described may offer reciprocal benefits to both constituent groups regarding communication, and that the development of a dedicated community of practice will enhance engagement of TMOs in health service improvement initiatives and advocacy. However, there are obstacles to overcome in order to attract a greater number of trainees and maximise the benefits from this initiative. [ABSTRACT FROM AUTHOR]

Introduction: Penicillin allergy labels are common. However, many penicillin allergy labels have been applied incorrectly and in fact represent penicillin intolerance. Patients with penicillin intolerance can receive penicillin antibiotics. The effect of penicillin intolerance labels on prescribing practices is uncertain. Methods: This multicenter retrospective cohort study included consecutive general medicine patients admitted to two tertiary hospitals over a 12-month period. Electronic medical records were reviewed for allergy and prescribing practices. Instances of penicillin prescription to patients with previously labeled penicillin allergies underwent case note review. Results: There were 12,134 individual hospital admissions included in the study. The number of admissions with a previous penicillin allergy label was 1,312 (10.8%) and with a penicillin intolerance label was 60 (0.5%). Penicillin allergy labels were associated with increased likelihood of being prescribed vancomycin (odds ratio 1.42, 95% confidence interval 1.16–1.75, p = 0.001) and moxifloxacin (odds ratio 20.0, 95% confidence interval 13.4–29.9, p < 0.001). Penicillin intolerance was not associated with increased likelihood of receiving these antibiotics. There were 75 admissions during which an individual with a penicillin allergy label was prescribed one of the specified penicillins and only one adverse reaction in this group. These cases included eight deliberate challenges and 15 cases in which allergy history clarification was sufficient to delabel the allergy. Conclusions: This study supports that prescribing practices differ between patients with penicillin allergy labels and intolerance labels. Penicillin challenges may be undertaken safely in the inpatient setting. Further studies are required to investigate how best to interrogate penicillin allergy labels in this cohort. [ABSTRACT FROM AUTHOR]

Participant demographics; age, gender, BMI, SGLT2i therapy status and insulin therapy status and ketone peak (measured pre- and postcolonoscopy) were combined into a multivariate linear regression analysis. Hamblin et al.[1] in their recent publication examine various associations with ketosis in the colonoscopy population. [Extracted from the article]

Preclinical studies in rodents demonstrated that all GLP-1 receptor agonists caused thyroid C cell tumours. We also wish to highlight a safety signal for thyroid cancer with glucagon-like peptide 1 (GLP-1) receptor agonists, which is a relevant issue to prescribers given the widespread use of these agents for obesity. A recent French study has raised concerns about this safety signal.[4] This population-based case-controlled study assessed the association between GLP-1 receptor agonist use and thyroid cancer in individuals with diabetes. [Extracted from the article]